No Data
No Data
Warner Pharmaceuticals (688799.SH) plans to explore investment opportunities in the medical and health sector in markets such as China and Southeast Asia through funds
Warner Pharmaceuticals (688799.SH) announced that the company plans to invest no more than RMB 40 million to pledge Hainan Heyi...
Warner Pharmaceuticals (688799.SH): Plans to exceed 100 million yuan to participate in the establishment of Queshan Huazi
Gelonghui, April 19丨Warner Pharmaceuticals (688799.SH) announced that in order to keep up with the trend and trend of macromolecular innovative drugs becoming mainstream drug use around the world, use the investment experience and resources of professional investment institutions to explore investment opportunities in innovative application fields related to the pharmaceutical industry, strengthen the company's capabilities in macromolecular drug research and development, and actively use external talents and capital to complete the company's new drug R&D transformation and product upgrade strategy with efficiency and low risk. The company now plans to work as a limited partner, Beijing Qushan Investment Management Co., Ltd., Hunan Jinyang Investment Group The limited company and other partners signed the “”
Warner Pharmaceuticals (688799.SH): Plans to build a “Green Intelligent Manufacturing Base (Phase I) with an annual output of 3,000 tons of high-end APIs and intermediates for no more than 650 million yuan
Gelonghui, April 19 | Warner Pharmaceuticals (688799.SH) announced that based on the strategic development plan, the company plans to invest no more than 650 million yuan to build the “Green Intelligent Manufacturing Base (Phase I) Construction Project with an annual output of 3,000 tons of high-end APIs and intermediates” through Zhigen Pharmaceutical's investment of no more than 650 million yuan. After the construction of the project is completed, it will further expand the production scale of the company's high-end APIs and intermediates, enhance the company's green and intelligent manufacturing capabilities, consolidate the company's ability to integrate raw materials and formulations, lay the foundation for the domestic and international industrialization layout of the company's high-end APIs and intermediate products, and enhance the company's industrial support and profitability
Warner Pharmaceuticals (688799.SH): Net profit of 60.5531 million yuan in the first quarter increased 21.90% year-on-year
Gelonghui, April 19: Warner Pharmaceuticals (688799.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 373 million yuan, up 4.38% year on year; net profit attributable to shareholders of listed companies was 60.5531 million yuan, up 21.90% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 44.2789 million yuan, up 0.28% year on year; basic earnings per share were 0.64 yuan.
Approval for Warner Pharmaceuticals (688799.SH) to issue convertible corporate bonds to unspecified targets expires
Warner Pharmaceuticals (688799.SH) announced that the company is obtaining approval to issue convertible corporate bonds to unspecified targets...
Private Companies Are Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥427m Last Week
Key Insights Significant control over Hunan Warrant PharmaceuticalLtd by private companies implies that the general public has more power to influence management and governance-related decisions 56%
No Data